Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations By Ogkologos - June 30, 2025 766 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR ESMO Welcomes European Parliament Resolution Marking World Cancer Day February 11, 2026 FDA Approves Avelumab for Urothelial Carcinoma Maintenance Treatment July 7, 2020 Mom Is Outraged After Finding Out Her Mother-In-Law Changed The Baby’s... May 6, 2019 Why I Work to Bridge the Gap Between People With Cancer... May 27, 2021 Load more HOT NEWS How cancer hijacks cell death: a new view of metastasis EMA Recommends Extension of Indications for Olaparib Cancer in My Community: Encouraging Cancer Screening in Estonia How to Find Reliable and Affordable Transportation During Cancer
